December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma CME Congresses . December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD CME Congresses . December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? CME Congresses . December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? December 7th- ASH 2025 Spotlight: The Rise of Golcadomide CME Congresses . December 7th- ASH 2025 Spotlight: The Rise of Golcadomide December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25? CME Congresses . December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25? December 6th- ASH 2025 Spotlight: The VERIFY Trial CME Congresses . December 6th- ASH 2025 Spotlight: The VERIFY Trial December 6th- ASH 2025 Spotlight: The HD21 Trial CME Congresses . December 6th- ASH 2025 Spotlight: The HD21 Trial December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network - PMC CME Congresses . December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network – PMC Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20
